Production of an inactivated rabies vaccine in primary dog kidney cells.

In this paper the large-scale production of a purified inactivated rabies vaccine in primary dog kidney cells cultivated in microcarrier culture is described. The potency in the NIH-test and the antigenicity of this vaccine in other animal experiments were comparable with the antigenicity of vaccine prepared in human diploid cells. The antibody response was greatly enhanced by the addition of AIPO4 as adjuvant. The results of an initial clinical trial are presented.